Neonatal exchange transfusion: Experience in Korea

Transfus Apher Sci. 2020 Jun;59(3):102730. doi: 10.1016/j.transci.2020.102730. Epub 2020 Jan 9.

Abstract

Background: Exchange transfusion (ET) is an established, efficacious, and reliable practice for severe neonatal hyperbilirubinemia, hemolytic disease of the newborn, and neonatal sepsis. This study assessed the indications and clinical outcomes of ET performed in a tertiary hospital in Korea.

Materials and methods: We studied 64 ET sessions performed on 23 neonates between March 1999 and March 2018. ET was performed based on estimated double volume exchange transfusion using fresh red blood cells and fresh frozen plasma. Patients' clinical information, including demographic data and ET indication, and laboratory data were collected pre- and post-ET.

Results: The most common ET indication was hyperbilirubinemia with hemolytic anemia due to non-ABO maternal blood group discrepancies. In three preterm babies, ETs were performed for severe anemia, leukocytosis, and hyperkalemia cases. Before ET, the patients showed slightly high WBC counts, low hemoglobin levels, and low platelet counts. After ET, blood examination revealed normal WBC counts, increased hemoglobin levels, and decreased platelet counts (all P < 0.001). Bilirubin levels decreased immediately after ET (P < 0.001). Electrolyte and C-reactive protein levels showed no significant changes after ETs. Adverse events occurred in 11 (47.8 %) patients; the most common were hypoxemia and hypotension. One infant experienced cardiorespiratory arrest due to hypercalcemia and was successfully resuscitated. No one died within 24 h of ET. However, five infants showed hyperbilirubinemia aggravation.

Conclusions: ET is an effective treatment modality for leukocytosis and hyperbilirubinemia with low mortality but involves common adverse events post-ET. This report provides an overview of current ET practices in Korea.

Keywords: Adverse event; Exchange transfusion; Hyperbilirubinemia; Indication.

MeSH terms

  • Anemia / therapy*
  • Exchange Transfusion, Whole Blood / adverse effects
  • Exchange Transfusion, Whole Blood / methods*
  • Female
  • Humans
  • Hyperbilirubinemia, Neonatal / therapy*
  • Infant, Newborn
  • Male
  • Republic of Korea